Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of FMT for C. Difficile in Solid Tumor Patients
NCT02770326Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- May 2016
- Primary completion
- Feb 2024
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Open-label trial of allogeneic fecal microbiota in Clostridioides difficile infection (CDI), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Number of Participants Evaluated for Infection During Treatment Intervention at 2 weeks. Started May 2016; status: completed.
02
Drugs
allogeneic fecal microbiota
03
Conditions
Clostridioides difficile infection (CDI)
Beyond the preview
Go deeper on NCT02770326.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02770326.